Because of 1.5 hours of trading?LOL. Look at the last 3 months. a 200% return in 3 months tells me that the market AGREES with me.
Lol. so middle aged women aren't replaced. Nobody ages eh?? US market barely scratched
Wrong. This is just another BRCA test that is designed for women who have family history. The beauty of BrevagenPlus is that it is designed for ALL women regardless of the family history and is much stronger predicted than BRCA tests. If anything, the New York Times article highlights the unique an powerful attributes of the product GENE has developed and is NOW selling.
Since 99% of the people here and 85% of the shares traded are day traders (both long and short), lets start a thread on the long term potential here. Lets start with potential:
The company (according to Yahoo Finance) has only a 30 million market cap. What are the expected revenues for this year? How much does one test cost? Revenue for next year? Profit margin? The company has sufficient cash it seems?? but comments on cash? What is the overall market? i.e. number of women over 35 per year who would be recommended the test?
FYI - I have been day trading this successfully for 2 months and am about 2k ahead. I started today with a trade and sold half and decided, what the heck, I am going long a bit on this one (only made $7.50 on todays trade but a profit is a profit). I have about 20% of my cash day trading and 80% in a variety of stocks, ETFs mutual funds, REITS and bonds.
well, did your extensive DD find out that the key statistics on yahoo finance are totally wrong. They just raised 21.8 million dollars. Great DD dude!
#$%$ Sorry!! What I meant was FDA denial expected April 2!! Capital raise of 21 million also needs to be returned at 20% interest. Bankruptcy imminent!!
Read the transcript: FDA clearance expected first week in April according to March 16 Conference call
You mean like JAZZ and Teva, some of the biggest biotechs around. JAZZ up from 0.8 to 170 in 5 years???? Nope dont buy an Israeli biotech. HMMM the La Jolla of biotech outside the US.
from skin lesion and perhaps BL1040. This number has been going up every week. I expect positive cash flow by next year and never again needing to sell shares.
Yes. They bought from BLRX - this was a cash raise. Mentioned in the Roth meeting as a capital raise! 100% sure
Cash position is 68.3 million dollars - ROTH presentation. 29.6 cash starting plus 10 million from NVT and 28.6 from secondary.
About 52 million outstanding shares
expected 1040 market 1 billion in the near term. Lets not forget people 1040 is CLOSE to marketing. It is almost ready to go!!